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ABSTRACT: Hepatocyte growth factor (HGF) is a heparin-binding, multipotent growth factor that transduces
a wide range of biological signals, including mitogenesis, motogenesis, and morphogenesis. Heparin or
closely related heparan sulfate has profound effects on HGF signaling. A heparin-binding site in the
N-terminal (N) domain of HGF was proposed on the basis of the clustering of surface positive charges
[Zhou, H., Mazzulla, M. J., Kaufman, J. D., Stahl, S. J., Wingfield, P. T., Rubin, J. S., Bottaro, D. P., and
Byrd, R. A. (1998) Structure 6, 109-116]. In the present study, we confirmed this binding site in a
heparin titration experiment monitored by nuclear magnetic resonance spectroscopy, and we estimated
the apparent dissociation constant (Kd) of the heparin-protein complex by NMR and fluorescence
techniques. The primary heparin-binding site is composed of Lys60, Lys62, and Arg73, with additional
contributions from the adjacent Arg76, Lys78, and N-terminal basic residues. The Kd of binding is in the
micromolar range. A heparin disaccharide analogue, sucrose octasulfate, binds with similar affinity to the
N domain and to a naturally occurring HGF isoform, NK1, at nearly the same region as in heparin binding.
15N relaxation data indicate structural flexibility on a microsecond-to-millisecond time scale around the
primary binding site in the N domain. This flexibility appears to be dramatically reduced by ligand binding.
On the basis of the NK1 crystal structure, we propose a model in which heparin binds to the two primary
binding sites and the N-terminal regions of the N domains and stabilizes an NK1 dimer.
Hepatocyte growth factor (HGF)1 is a potent mitogen,
motogen, and morphogen which targets a wide range of cells
(1, 2). Extensive studies have established that HGF mediates
epithelial-mesenchymal interactions and somatic cell migra-
tion, which are crucial for the development, maintenance,
and regeneration of various tissues and organs (3). HGF has
been implicated in many human diseases, including acute
and chronic renal failure, liver fibrosis/cirrhosis, and cancer
(3, 4). Mature HGF consists of an N-terminal (N) domain
and four “kringle” domains (K1-K4) in its R-chain and a
serine protease homology domain in its â-chain (2). The N
domain contains two disulfide linkages which are also found
in the N-terminal domains of plasminogen and macrophage
stimulating protein. The â-chain has no protease activity due
to residue changes in the catalytic triad. The N and K1
domains of HGF appear to be involved in binding to the
receptor of HGF, the proto-oncogene product c-Met (5).
Experiments suggest that the receptor-binding characteristics
of HGF are primarily localized in K1 (6, 7; J. S. Rubin and
D. P. Bottaro, unpublished results).
In addition to high-affinity binding to c-Met, HGF also
binds to glycosaminoglycans, such as heparan sulfate (HS),
associated with the membrane and extracellular matrix (8-
10). HS is similar in composition and structure to heparin,
and both bind to HGF with similar affinity. The effect of
exogenous heparin on HGF signaling resembles that observed
in fibroblast growth factor (FGF) signaling (11-13). Heparin
is able to enhance the biological function of HGF under
certain conditions, possibly by stimulating ligand and recep-
tor dimerization (10, 14, 15), although it also has been
observed to inhibit HGF activity in other circumstances (16).
The apparent dissociation constant (Kd) was estimated to be
in the nanomolar range (1-50 nM) for HGF binding to
heparin or heparan sulfate in a membrane-binding setting
(9) or in a biosensor-based assay (17). Two naturally
occurring HGF isoforms NK1 (extending to K1) and NK2
(extending to K2) also bind c-Met and heparin and can
function as agonists or antagonists of the full-length HGF
(5, 10, 14, 18). A heparin-binding constant similar to that
for uncleaved HGF was found for NK2 by surface plasmon
resonance techniques (19).
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Following the report that the N domain retains the heparin-
binding ability of full-length HGF (10), we determined the
solution structure of this domain (20). Because interaction
between heparin and protein is predominantly electrostatic
(21), the structure immediately suggested a potential heparin-
binding site which has a distinct cluster of positively charged
residues. The recent crystal structure of the HGF isoform
NK1 (22, 23) reveals a nearly identical structure of the N
domain within a “head-to-tail” NK1 dimer in the asymmetric
unit. Although the dimer arrangement of NK1 suggests that
heparin may have affinity to regions outside the N domain
(22, 23), mutational and biochemical data support the idea
that the primary heparin-binding site resides in the N domain.
In this study, we conducted a series of heparin titration
experiments that confirmed the previously proposed heparin-
binding site in the N domain. The Kd of heparin-N domain
binding in solution, estimated using nuclear magnetic
resonance (NMR) and fluorescence techniques, is in the
micromolar range, significantly lower than that found for a
longer HGF fragment (NK2) or full-length HGF when
assayed with membrane preparations or heparin attached to
a solid phase. We examined the dynamic properties of the
heparin-binding site by measuring the 15N spin relaxation
parameters of the N domain. These data indicate that the
heparin-binding region undergoes conformational exchange
on a microsecond to millisecond time scale in the absence
of the ligand. The protein structure is stabilized upon heparin
binding, as shown by increased resistance to disulfide bond
reduction in the presence of heparin. We also conducted
binding studies using a disaccharide heparin analogue,
sucrose octasulfate (SOS). SOS has a structure and polya-
nionic character similar to those of the disaccharide repeating
unit of heparin (24). Either in soluble form or as an insoluble
aluminum salt, SOS has been used to treat stomach ulcers,
and it appears to function by binding and stabilizing FGF
(24-26). We observed that SOS binds to the HGF fragments
N and NK1 at nearly the same region as that found for
heparin binding. These results suggest a model of heparin-
induced dimerization involving heparin binding to the
primary sites and the N-terminal basic residues in the N
domains of an HGF dimer.
MATERIALS AND METHODS
Sample Preparation. The N, K1, and NK1 fragments of
HGF were expressed in Escherichia coli, refolded, and
purified as previously described (20, 27). Isotope-labeled
proteins were expressed in M9 minimal media, containing
either 15NH4Cl or both 15NH4Cl and 13C-labeled glucose. All
protein samples were dissolved in 50 mM sodium phosphate
and 100 mM NaCl at pH 6.8 prior to the titration
experiments. NMR data were collected at 30 °C on a Varian
UnityPlus 500 or 600 MHz spectrometer equipped with
Z-spec triple resonance probes with pulsed field gradients
(Nalorac Corp.), except as otherwise stated.
Heparin and SOS Titrations. Porcine heparin, with an
average molecular mass of 3 kDa (10-15 monosaccha-
ride units) or 6 kDa, was purchased from Sigma. Purity of
both heparin samples was checked by 1H NMR spectroscopy
at 70 °C (28, 29) and found to contain <2% dermatan sulfate.
SOS was purchased from Toronto Research Chemicals, Inc.
In the NMR experiments, the titration was done by adding
concentrated heparin or SOS solution (5-25 mM) to samples
of the N domain or NK1 contained in 5 mm NMR tubes. At
each ligand:protein ratio, a two-dimensional 1H-15N cor-
relation spectrum or a one-dimensional 1H spectrum was
recorded, and changes in resonance position were examined.
Fluorescence Spectroscopy. Tyramine- and FITC-tagged
heparin (30), with an average molecular mass of 4 kDa, was
purchased from Sigma. The heparin was dissolved in water
at a concentration of 5 íg/mL heparin. Fluorescence
measurements were carried out in either a Spex Fluoromax-2
(Instruments SA) or a Shimadzu RF-5301PC (Shimadzu
Scientific Instruments, Inc.) spectrofluorometer. The buffer
was 50 mM sodium phosphate, pH 6.8, containing 100 mM
NaCl. Tryptophan (Trp) emission spectra from the N and
NK1 fragments of HGF were acquired in the ratio mode by
exciting the sample at either 280 or 297 nm (2 nm bandwidth)
and collecting the emission intensity between 290 and 550
nm (5 nm bandwidth) at 0.5 nm intervals for 0.3 s at each
wavelength. Buffer subtraction was carried out to generate
net spectra, which underwent zeroing at 540 nm. Spectral
deconvolution of overall emission spectra was performed by
subtraction of the spectrum obtained at 297 nm excitation
(where Trp photoselection is maximal) normalized to the
emission intensity at 380 nm (where Tyr does not contribute)
from the overall emission spectrum taken with 280 nm
excitation. Such a spectral manipulation yielded the net Tyr
emission spectrum of the sample. Relative contributions of
the Tyr and Trp populations to the overall emission were
determined from the area under the spectra. Excitation spectra
were acquired ratiometrically between 240 and 340 nm at
0.25 nm intervals with a 1 nm bandwidth and 1 s integration
time, by monitoring the emission intensity at 360 nm.
Excitation spectra were corrected for solvent background and
lamp output intensity.
Fluorescein emission spectra from FITC-labeled heparin
were acquired with 460 nm excitation and 2 nm bandwidth
and measured between 480 and 700 nm at 0.5 nm intervals
with a 5 nm bandwidth and 0.3 s integration time. Excitation
spectra were obtained with identical settings, except that the
emission was monitored at 550 nm and the excitation
monochromator moved from 340 to 540 nm. Samples were
placed in dual path length (0.2  1.0 cm) Suprasil quartz
cuvettes (Uvonic Instruments, Inc.) in a thermostated holder
at 25 °C.
15N Relaxation. The longitudinal (T1) and transverse (T2)
relaxation times of backbone amide 15N nuclei and 15N{1H}
nuclear Overhauser enhancements (NOEs) for the N domain
were measured at proton frequencies of 500 and 600 MHz
with the use of pulsed field gradients (31, 32). Two-
dimensional 1H-15N correlation spectra were collected with
the following 15N relaxation delays: 11.1, 55.5, 133.2, 188.7,
277.5, 444.0, 555.0, 721.5, 832.5, and 999.0 ms for T1 and
15.5, 31.0, 46.5, 77.4, 92.9, 108.4, 123.9, 139.4, 154.9, and
185.9 ms for T2. The recycle delays between the scans were
2 s for the T1 and T2 measurements. The relaxation time
constants were extracted by fitting the intensity data of
resolved amide NH cross-peaks to a single-exponential decay
function of the delay time. Heteronuclear 15N{1H} NOEs
were measured as the ratio of the peak intensities in the
spectrum collected with 1H saturation during a 3 s recycle
delay and a spectrum without 1H saturation.
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The relaxation data were analyzed using the “model-free”
approach (33) and the program ModelFree (34). For a nearly
spherical molecule undergoing isotropic tumbling, the spec-
tral density that governs the spin relaxation is described by
an overall rotational correlation time (ôm), a correlation time
for internal motions (ôe), and an order parameter (S2):
where ô ) ômôe/(ôm + ôe). A linear combination of J(ö) at
different frequencies and with coefficients for dipolar
coupling and chemical shift anisotropy gives rise to the
relaxation rates R1 (1.0/T1) and R2 (1.0/T2) (34). An exchange
term (Rex) on a microsecond-to-millisecond time scale may
contribute to R2, which shortens T2 and causes line broaden-
ing (34). To a first-order approximation, internal motions
were ignored (ôe ) 0), and T1/T2 (or R2/R1) ratios were fit to
extract ôm by minimizing the function:
where cal and exp denote calculated and experimental values,
respectively, and the sum was obtained for selected residues
and data at the two fields. Only residues with 15N{1H} NOE
values larger than 0.65 and T1/T2 values within 1 standard
deviation around the average were included in the fitting.
With ôm fixed at the best value calculated, the internal motion
parameters S2 and ôe and the exchange rate Rex were extracted
by fitting R1, R2, and NOE for each residue, through the
minimization of the function:
RESULTS
Identification of the Heparin- and SOS-Binding Sites. The
isolated N domain bound to heparin and SOS, as shown by
the peak movements in the 1H-15N correlation spectrum with
the addition of the ligands (Figure 1). The cross-peak
displacements continued with each addition of ligands until
saturation, indicating that the binding was on a fast-exchange
time scale relative to the resonance frequency differences
between the free and bound proteins. The residues that
exhibited large changes in amide 1H and 15N resonances upon
heparin binding were clustered in a surface formed by
residues 60-80, which consist of a strand (â2), an R-helix,
and a loop (Figures 2 and 3). The involvement of the loop
in heparin binding was indicated by large displacements of
the Arg76 and Leu80 amide resonances with the addition of
heparin, although the amide resonances of several residues
in the loop, including Lys78, have not been reliably assigned
in both the free and bound proteins. SOS bound to HGF at
nearly the same surface as heparin (Figure 3), but the region
affected by binding appeared to be smaller and the most
affected region was Arg73-Leu80. This was not surprising,
since SOS is much smaller than a typical heparin molecule.
Substantial resonance changes were also observed for
residues 38-42 in the N-terminal, short helical region for
both heparin and SOS binding. These changes may be due
to contact of this region with the primary heparin-binding
site in the structure or most likely the involvement of several
basic residues in the N-terminal region of the N domain in
ligand binding.
These observations confirmed the previous prediction of
a heparin-binding site based on surface charge distribution
(20). Heparin binding primarily involves Lys60, Lys62, and
particularly Arg73 (Figure 3). These residues showed large
changes in chemical shift upon ligand binding. Interestingly,
a sulfate ion was coordinated by these residues in one form
of the NK1 crystal structure (23). Basic residue clusters that
are remote from this binding center did not seem to have
significant interactions. In particular, several basic residues
in a tight turn (Lys91/Arg93/Lys94) had only small changes
in their amide chemical shifts. In SOS binding, the most
significant changes in chemical shift were observed around
Arg73 and in the following loop region (Asn77-Leu80), and
moderate changes were observed in the N-terminal region
and strand â2. Several new peaks in the 1H-15N correlation
FIGURE 1: Overlay of portions of the 1H-15N correlation spectra of the N domain of HGF in the presence and absence of heparin (a) or
SOS (b). The spectrum of the free protein is in black, and the spectrum in the presence of ligand is in red. The ratio of the ligand:protein
concentration is 1:5 in (a) and 1:3 in (b).
J(ö) ) S2ôm/[1 + (öôm)2] + (1.0 - S2)ô/[1 + (öô)2]
E ) ∑i,500,600{[(R2/R1)cal - (R2/R1)exp]/(R2/R1)exp}2
E ) ∑i,500,600{[(R1,cal - R1,exp)/R1,exp]2 + [(R2,cal -
R2,exp)/R2,exp]2 + [(NOEcal - NOEexp)/NOEexp]2
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spectrum of the SOS-bound protein came from the loop
region and the N-terminal residues, due to the tightening and
reduced mobility of the structure upon ligand binding (H.
Zhou and R. A. Byrd, manuscript in preparation). It is
interesting to note that the helical and the loop regions also
contain several polar residues which are aligned linearly
along one surface of the helix at the edge of the heparin-
binding site. Among these polar residues, Asn72, Thr75, and
Asn77 exhibited large resonance changes upon ligand
binding. The polar side chains of these residues may form
hydrogen bonds with heparin, as seen in several heparin-
FGF complex structures (13, 35).
In addition to the significant resonance changes mentioned
above, several residues around Cys96 also showed large
displacements of amide resonances in the presence of
heparin. Cys96 resides in strand â4, which aligns with strand
â2 through hydrogen bonds. The changes around Cys96 are
probably due to structural rearrangement at the binding
surface that is transduced by the disulfide linkage between
Cys96 and Cys70. Smaller resonance changes occurred in
the same region in SOS binding, indicating that strand â2
was not extensively involved in SOS binding. This finding
is consistent with the primary binding site for SOS being
localized within the R-helix and the following loop region.
Heparin and SOS Binding of NK1. Similar NMR titration
experiments were conducted for NK1. Heparin and SOS
binding to NK1 was substantially different from binding to
the N domain. Heparin caused precipitation of NK1, although
an excess of heparin slightly decreased the precipitation. With
the addition of heparin, the amide peaks remained at the same
position but dropped in intensity and eventually all peaks,
except for a few intense peaks, disappeared, suggesting the
formation of a large heparin-NK1 complex. The remaining
intense peaks were mostly from side chain amide groups and
from a highly flexible region of the protein. The precipitation
prevented us from examining the resonance changes of NK1
upon binding to heparin.
SOS aggregated NK1 to a lesser extent than heparin. A
small amount of precipitation was observed after SOS was
added to the protein sample, but 1H-15N resonances, from
protein molecules in solution, could still be detected (Figure
4). The exchange between free and bound proteins was fast
relative to the resonance frequency differences between free
and bound conformations, as shown by the presence of a
single set of cross-peaks for the residues involved in binding
and the continuous movement of the peaks with the addition
of SOS. The residues that have large changes in chemical
shifts upon SOS binding can be assigned almost entirely to
the N domain. The direction and amplitude of the peak
movement closely resemble those in the N domain-SOS
binding, indicating essentially the same ligand binding sites
and similar structural changes in the N domain and NK1.
Although K1 did not bind to a heparin-Sepharose column
FIGURE 2: Amide resonance frequency changes of the N domain
of HGF upon binding to heparin (a) and SOS (b). The frequency
change represents the total displacement of the amide cross-peak
in the 1H-15N correlation spectrum with the addition of the ligand,
(¢H + ¢N)1/2, measured in hertz at the proton field of 500 MHz.
The ratio of the ligand:protein concentration is 1:5 in (a) and 1:3
in (b). The maximum change in (b), indicated by an asterisk, is
206 Hz for Asn77 and is truncated at the top for better scaling of
the data.
FIGURE 3: Schematic representation of the resonance changes for
the N domain of HGF upon binding to heparin (left) or SOS (right).
The bottom two figures result from a 90° rotation of the top figures.
The color scheme corresponds to an increasing change in resonance
frequency, from cyan to gold, with the addition of the ligand. The
amplitude of the resonance frequency change is taken from Figure
2. A 12-residue heparin (42) or SOS (25) is shown above the protein
structure, with sulfur atoms in yellow, oxygen atoms in red, and
carbon atoms in green. The orientation of the ligand relative to the
protein is not known. The heavy-atom side chains of the basic
residues situated within the region of ligand binding are shown in
red. The N-terminus of the protein is located in the upper left corner
of the structure. The plot was generated with the program
MOLMOL (45).
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in a previous study (10), we observed that several amide
NH resonances from the K1 domain in NK1 moved with
the addition of SOS. Addition of a 10-fold excess of SOS to
a K1 sample also caused peak movements for these amide
resonances, indicating that SOS weakly binds to the isolated
K1 domain and to the K1 domain within NK1.
Despite the slight aggregation of NK1 with SOS, the
observed NK1 resonances were not significantly broadened
relative to the peaks in the free protein (Figure 4), indicating
that at least one mode of SOS binding to NK1 does not
involve significant formation of dimers or oligomers. The
formation of NK1 dimer or oligomers would increase the
molecular mass of the complex to at least 44 kDa and would
cause significant line broadening or even resonance disap-
pearance. Because SOS is much shorter than a typical heparin
molecule, the data from NK1-SOS binding does not rule
out that heparin is able to oligomerize NK1 and induce a
more stable, high-molecular-weight complex with NK1.
Heparin-induced NK1 oligomerization was indicated by the
aggregation of NK1 in the presence of heparin. Binding of
heparin to the interdomain interface within an NK1 or NK2
dimer has also been suggested on the basis of the recent
crystal structures of NK1 (22, 23). Such a binding mode
requires the ligand to be long enough to bridge two or more
domains within or between the monomers.
Heparin-Induced Oligomerization of the N Domain. In the
case of both heparin and SOS binding, the resonance peak
positions in the isolated N domain exhibited a clear
dependence on ligand concentration, indicating a chemical
shift averaging effect due to an apparent fast exchange
between free and bound conformations. The binding curves
could not be fit with a simple two-site fast-exchange model,
P + H T PH, which involves only monomeric protein (P)
and heparin (H) with a single binding site on each molecule
(Figure 5). The fast transition in chemical shift from the free
state to the bound state suggests ligand-induced oligomer-
ization of the protein or multiple, cooperative binding sites
for heparin. A model which included a 1:2 heparin-protein
complex in the bound state significantly improved the fit
and including a 1:4 complex further improved the fit (Figure
5). The formation of a complex involving two or more
protein molecules in the presence of heparin was also
indicated by severe line broadening of the amide resonances
in the presence of an excess of ligand.
Structural Flexibility of the N Domain. To determine
whether the heparin- and SOS-binding region is dynamically
different from the remainder of the free protein, we collected
and analyzed the 15N relaxation data at field strengths
corresponding to 1H frequencies of 500 and 600 MHz for
the N domain (Figure 6). Also of interest was the dynamics
of the two extended loop regions encompassed by residues
47-59 and 100-116. By simultaneously fitting the T1/T2
ratios at the two fields, we obtained an overall rotational
correlation time of 6.5 ns, which is reasonable for a nearly
spherical, monomeric protein of 11 kDa. Residues 72-85,
which include the C-terminal half of the R-helix and the loop
region (Asn77-Pro81), exhibited significantly reduced T2
values. A chemical shift exchange term (Rex) was added to
the fitting to account for this T2 reduction, leading to Rex
values larger than 1 Hz for most residues in this region.
Residues 75 and 76 had the shortest T2 values, which led to
Rex values of 5 Hz. Several residues in the loop region
immediately after the R-helix were not observed in the 1H-
15N spectrum. These results indicate that a large portion of
the heparin-binding region and particularly the loop region
are involved in motions on a microsecond-to-millisecond
time scale. The two extended loop regions showed slightly
FIGURE 4: Overlay of portions of the 1H-15N correlation spectra
of NK1 in the presence (red) or absence (black) of SOS. The straight
lines indicate the change of amide peak positions when an excess
of SOS was added to the protein sample. The peaks inside the box
are from the K1 domain.
FIGURE 5: Binding of multiple protein molecules by a single
heparin. The chemical shift of Arg73 amide 15N (open circles) in
the isolated N domain of HGF is shown as a function of the total
heparin concentration. The solid line is the theoretical best fit of
the data, using a model assuming a heparin:protein stoichiometry
of 1:1, 1:2, and (1:2 + 1:4) of the complex. The following equilibria
are assumed: P + H T PH for the 1:1 complex; 2P + H T P2H
for the 1:2 complex; 2P + H T P2H, 2P + P2H T P4H for the
(1:2 + 1:4) complex. The equilibrium equations can be found, for
example, in ref 46. The measured chemical shift is taken as the
fractional average of those in the free and bound protein under fast-
exchange condition. We also assume that there is only a single
ligand-binding site in the protein, with a single chemical shift value
for the bound state. A separate dissociation constant is assumed
for each equilibrium, and the total differences between the measured
and calculated chemical shifts were minimized in a grid-search
manner by varying the apparent dissociation constants and the
chemical shifts of the bound state. Due to the large number of
unknown parameters and the small dissociation constant relative
to the protein and ligand concentrations used, this analysis is only
used to show the presence of ligand-induced oligomerization and
should be viewed qualitatively.
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reduced order parameters, especially in the regions of
residues 54-59 and 107-115, but overall these extended
loops exhibited a high degree of rigidity. The N-terminal
seven residues were not observed in the NMR spectrum.
Their absence apparently resulted from line-broadening
effects from high levels of mobility on a microsecond-to-
millisecond time scale, as indicated by the increasing trend
of Rex and ôe toward the N-terminus.
Increased Protein Stability against Disulfide Bond Reduc-
tion in the Presence of Heparin. Because heparin and SOS
stabilize the structure of FGF (13, 24-26), we investigated
this effect for HGF by observing the increased stability of
HGF against chemical reduction in the presence of heparin.
The N domain contains two disulfide bridges (Cys70-Cys96
and Cys74-Cys84). In the absence of heparin, a 10-fold
molar excess of DTT denatured the protein in approximately
24 h (Figure 7), presumably by disrupting the “hairpin loop”
structure (20) linked by the disulfide bridges. In the presence
of heparin, however, the protein remained folded for more
than 96 h in the presence of DTT. The solution structure of
the N domain (20) reveals that the Cys70-Cys96 bond is
entirely buried in the core of the protein, whereas the Cys74-
Cys84 bond is covered by the flexible loop (Asn77-Pro81).
The results of the chemical reduction experiment support
the notion that the loop region formed by residues 77-81 is
flexible in the free protein and is able to open up and allow
the reducing agent access to at least one of the disulfide
bonds. The data indicate that the loop region became more
rigid when heparin was bound to the protein and ligand
binding prevented DTT from coming in contact with the
disulfide bonds. Because the two basic residues in the loop
region, Arg76 and Lys78, lie near the edge of the heparin-
binding surface, they probably play a facilitating role in
binding heparin.
Measurement of the Kd of Heparin-N Domain Binding
by Fluorescence Spectroscopy. To study heparin-N domain
interaction at a concentration comparable to the Kd, we
conducted a series of titration experiments using fluorescence
techniques. The emission spectrum of the N domain was
clearly the composite of multiple bands (data not shown).
The resolved Trp band was notably red-shifted, with an
emission maximum (354 nm) typical of indole side chains
that are exposed to the solvent environment. The Trp band
was also relatively broad (5800 cm-1), with a line width that
was much larger than that measured from the excitation
spectrum (4850 cm-1) of the N domain. Such a large line
width for the photoselected Trp emission cannot be explained
by a Tyr to Trp energy transfer process at the singlet level.
Rather, it must reflect the inhomogeneous microenvironment
of the emitting fluorophore, stemming from sampling of
multiple locations of different polarity by the sole Trp
fluorophore in the N domain. The N domain structure shows
that Trp98 is partially buried and surrounded by the positively
charged side chains of Lys and Arg. This unusual environ-
ment for a hydrophobic indole moiety is in good agreement
with the low fluorescence emission of this particular residue.
The intrinsic fluorescence emission of the N domain did
not change significantly upon addition of heparin or SOS
sodium salt. Association of heparin with the N domain did
apparently occur, since addition of heparin to the N domain
complexed with fluorescein-labeled heparin displaced the
latter (see below). Addition of heparin to NK1 resulted in
precipitation, precluding further study of the interaction. To
quantify the binding of heparin to the N domain, we used a
commercial preparation of FITC-labeled heparin (28) (aver-
age molecular mass 4 kDa) in the binding assays. Spec-
trofluorometric characterization of the labeled material
showed excitation and emission maxima at 492 and 514 nm,
respectively, which are typical of the fluorescein moiety.
Addition of saturating amounts of the N domain to FITC-
heparin resulted in a 44% ((1%) reduction in the fluorescein
emission intensity. Analysis of such equilibrium binding
FIGURE 6: 15N relaxation data of the N domain of HGF. The left panels show the longitudinal (T1) and transverse (T2) relaxation times and
the 15N-1H NOE factors at the 1H field of 500 MHz. The right panels show the calculated order parameter (S2), correlation time of internal
motions (ôe), and exchange rate (Rex). The secondary structure is shown at the bottom of the left and right panels. Helices are indicated by
rectangles and â-strands by arrows. The region that contains the primary heparin-binding site is indicated by the solid rectangle and arrow.
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isotherms according to a Langmuir model (36), which
describes independent binding to isolated sites, resulted in
rectilinear traces (R2 > 0.996) in double-reciprocal plots
(Figure 8) of 1/¢F vs 1/[ligand]free, from which we derived
a dissociation constant of 0.17 ((0.02) íM and a stoichi-
ometry of 0.82 ((0.25):1 for the interaction of FITC-heparin
with the N domain (duplicate determinations). Any possible
effect of the hydrophobic fluorescein label on the interaction
with the N domain was investigated in competition experi-
ments with unlabeled heparin.
Displacement of FITC-heparin from the N domain was
attempted by addition of unlabeled heparin (average molec-
ular mass 3 kDa) to a preformed complex. Although
displacement was observed and rapid reequilibrium was
achieved under our experimental conditions, a significant
excess of unlabeled heparin was required for a 50% displace-
ment, suggesting that the interaction of the N domain with
FITC-heparin was about 1 order of magnitude stronger than
with the unlabeled material. Stepwise titrations of the N
domain into a mixture of heparin and FITC-heparin in a
1:1 or 9:1 molar ratio confirmed this finding and showed a
7-fold higher affinity of the N domain for FITC-heparin,
relative to unlabeled heparin. Thus, the binding affinity of
HGF-N for heparin was determined as 1-2 íM.
DISCUSSION
Primary Heparin-Binding Site. We have identified the
primary heparin-binding site in the N domain of HGF
through heparin and SOS titration experiments. In the well-
characterized FGF system, studies of heparin-FGF binding
have shown the extreme complexity of the heparin-protein
interactions that involve multiple binding sites in the protein,
the formation of protein dimers and tetramers in addition to
the monomeric species, and several spatial configurations
of the oligomer and heparin (11). Given the multidomain
organization of HGF and the possible existence of additional
binding sites outside the primary site in the N domain, the
HGF-heparin interaction is likely to be even more complex.
This study focuses on the primary heparin-binding site in
the N domain and represents the first step toward under-
standing the various modes of HGF-heparin interaction.
The primary heparin-binding site identified in this paper
consists of Arg73, Lys60, and Lys62, with additional
contributions from Arg76 and Lys78. This finding is
consistent with the significant reduction in heparin affinity
when Arg73 or Lys78 was substituted with alanine in a
naturally occurring HGF variant, dHGF (37), and the nearly
complete loss of heparin affinity for the group mutation
R73E/R76E/K78E of HGF (19). On the other hand, alanine
subsitution of Lys91, Arg93, and Lys94 has almost no effect
on heparin affinity (10, 37), consistent with the small
chemical shift changes observed when heparin was added.
Therefore, these residues are not part of the primary heparin-
binding site.
InVolVement of the N-Terminal Basic Residues in Heparin
Binding. There is published evidence that indicates the
N-terminal basic residues are directly involved in heparin
binding. Alanine substitution of the four basic residues
(RKRR) near the N-terminus resulted in a 32% reduction in
heparin-binding ability of full-length dHGF (37). Because
this region is flexible in the absence of ligand, mutations in
this region are unlikely to affect the native fold of the protein.
Consequently, the effects observed in the alanine substitution
studies probably reflect the heparin affinity for this region.
Isolation of heparin-binding fragment peptides through
limited protease digestion also indicated an important role
FIGURE 7: Increased stability of the protein against disulfide bond
reduction in the presence of heparin. A 10-fold excess of DTT was
added to the isolated N domain samples at the concentration of 50
íM in the absence (left) or presence (right) of 1 mM heparin. One-
dimensional 1H NMR spectra were collected after the specified time
indicated inside each panel. Unfolding of the protein in the absence
of heparin is indicated by the collapse of the proton resonance
toward random-coil values and was detected within approximately
24 h after the addition of DTT. The spectrum remained unchanged
for more than 96 h in the presence of heparin.
FIGURE 8: Double-reciprocal plot for the interaction of the N
domain of HGF with FITC-labeled heparin. The reciprocal of the
free NK1 concentration (1/[L]free) was plotted vs the reciprocal of
the fractional, normalized change in fluorescence emission intensity
(1/¢F). Points were fitted by linear regression, which yielded a
rectilinear trace that indicates the limiting quenching at saturation
and the binding affinity of the interaction. Experimental conditions
are reported in Materials and Methods.
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of the N-terminal region in heparin binding (38). In our
studies, we observed significant resonance frequency changes
and reduction of flexibility in the N-terminal region upon
ligand binding, consistent with direct contact of this region
with the ligand. However, our data do not suggest that these
basic residues form an independent binding site with an
affinity comparable with that of the primary binding site. If
both regions bind heparin independently and with nearly
equal affinity, the saturation of binding sites in the protein
would be much slower than we observed. Together, the
published mutation data and the data presented here suggest
that heparin binding involves additive contributions from
three regions: the primary binding site formed by Arg73,
Lys60, and Lys62; the N-terminal basic residues; and the
flexible loop region (Asn77-Leu80).
Heparin Affinity of the Isolated N Domain. In our titration
experiments, which were monitored by both NMR and
fluorescence and covered a protein concentration range from
upper nanomolar to millimolar, we observed a micromolar
Kd for the isolated N domain. This dissociation constant is
significantly higher than the nanomolar Kd observed for the
interaction of the full-length protein or NK2 with surface-
immobilized ligands (9, 17, 19). Increasing the pH from 6.8
to 7.4 or the salt concentration from 100 to 200 mM in our
NMR experiments did not have a significant effect on the
binding (data not shown). This discrepancy in apparent
binding affinity can be attributed, in part, to the differences
of binding to surface-associated heparin-like molecules,
subject to two-dimensional diffusion, versus binding in
solution, subject to three-dimensional diffusion (12, 39). It
may also result from differences of the oligomerization ability
between HGF fragments of different lengths (vide infra) and/
or the existence of additional binding sites outside the N
domain. Earlier experiments also implicated a role for the
K2 domain in heparin binding, evidenced by the loss of
heparin affinity when K2 was deleted from HGF (40). A
weak association of K1 with SOS was detected for both the
NK1 and K1 fragments in our NMR experiments, and this
finding is consistent with the fact that a HEPES molecule is
bound to K1 in one crystal structure of NK1 (23). The
weakness of this interaction implies that the binding is
nonspecific.
It is worth noting that fluorometric titrations are consistent
with a 1:1 complex between the N domain and heparin,
whereas a 3 ((1):1 stoichiometry was inferred from NMR
titration (Figure 4). This difference is probably not due to
interference from the fluorescent label, since (1) the label is
attached to the nonreducing end of heparin and leaves the
antithrombin III binding sites unmodified and (2) the label
does not perturb the anticoagulant activity of heparin (30).
The larger size of FITC-heparin (4 kDa) relative to the
unlabeled heparin used (3 kDa) also makes the effect of
the fluorescent label less likely. This difference in the
estimated stoichiometry probably results from multiple
binding sites in heparin with different affinities to the protein,
which is very plausible given the nearly symmetrical, helix-
like structure of free (41, 42) and bound (13, 35) heparin. It
is conceivable that, if binding sites with dissimilar affinity
are present in heparin, the higher concentration regime (by
2-3 orders of magnitude) of the NMR experiments could
result in their occupancy with the N domain. Analysis of
NMR titrations yielded an approximate apparent binding
constant of 15 íM, which lends support to this hypothesis.
Heparin Binding to the N Domains in an NK1 Dimer. No
evidence from our NMR experiments suggests that the N
domain and NK1 have significant dimer or oligomer content
in the absence of heparin, although a small amount of dimer
was previously observed by cross-linking experiments (10,
14). In the presence of heparin or other sulfated oligosac-
charides, significant amounts of dimer or oligomer were
observed for both FGF (11, 12, 43) and HGF (10, 14, 15,
22). On the basis of the NK1 crystal structure, several
possibilities of heparin-induced HGF dimerization have been
proposed, although the physiological significance of the
dimer structure is unknown. These possibilities include
binding of a single heparin molecule to the primary site in
one protomer and Lys91/Arg93 of the N domain in the other
protomer (22) and binding of a long heparin molecule to an
extended, positively charged groove at the interface between
the N domain and both kringle domains in an NK2 monomer
(23). The latter arrangement is unique since the proposed
binding site lies outside the primary binding site.
Here we propose another possibility that takes into account
heparin binding to the primary sites and the N-terminal
residues in an NK1 dimer. The crystal structure of NK1
shows that the N-terminal segments from the two subunits
in the dimer are positioned next to each other at the center
of the dimer, with the two primary heparin-binding sites
situated nearby (Figure 9). A heparin molecule with 10 or
more saccharide residues is long enough to bridge the two
primary binding sites and establish additional favorable
electrostatic interactions with the N-terminal protein segments
in the middle. Any steric interference of the N-terminal
residues with heparin could be compensated by the flexibility
of both this segment and heparin. The length of the heparin-
binding region in this model is consistent with reports of
the minimal size of the oligosaccharide (>10-12 residues)
required for optimal binding to HGF (44). Our model
proposes additive interactions of a single heparin molecule
with four regions in the protein dimer: the two major-binding
sites at either end of the binding region and the two
N-terminal segments in the middle (Figure 9). The observed
flexibility of the N-terminal segment, which is reduced upon
ligand binding, permits an adaptive recognition to the
heterogeneous glycosaminoglycans. Although a shorter oli-
gosaccharide could bind to each individual site, it would not
stabilize the dimer as well as a longer heparin molecule (15).
This suggestion is supported by the finding that the minimal
oligosaccharide that has significant affinity for HGF or is
able to enhance HGF-dependent mitogenesis is a hexasac-
charide (15, 44).
Besides the supporting evidence indicated above, our
model is also consistent with the fact that receptor- and
heparin-binding regions in HGF are for the most part distinct
(10, 19). It has been shown that K1 retains most of the
receptor-binding determinants (6, 7) while the N domain
retains most of the heparin-binding determinants (10). Indeed,
most of the residues in K1 (Glu159, Ser161, Glu195, and
Arg197) that were found to be significant in receptor binding
(7) are located on the opposite side of the NK1 molecule
from the heparin-binding region, as proposed in our model.
This NK1-heparin-binding model maximizes the interaction
between a single heparin molecule and the N domains in a
NK1 dimer and minimizes binding of heparin to other
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domains in HGF. This observation suggests that heparin does
not significantly alter the structure of the receptor-binding
sites, and its role is to bring two or more HGF and, in turn,
receptor molecules together in a biologically active, oligo-
merized state. This model may assist in determining whether
the dimer arrangement in the NK1 crystal structure has
physiological significance.
SUPPORTING INFORMATION AVAILABLE
Two tables containing the T1, T2, and NOE values from
the 15N relaxation measurement and the extracted dynamics
parameters for the N domain of HGF. This information is
available free of charge via the Internet at http://pubs.acs.org.
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